Future of toxicogenomics and safety signatures: balancing public access to data with proprietary drug discovery

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.8, Iss.5, 2007-05, pp. : 425-430

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Toxicogenomics in drug safety assessment

By Hewitt Philip Walijew Alexandra

Pharmacogenomics, Vol. 9, Iss. 4, 2008-04 ,pp. : 379-382

Future Medicine

Access to resources Recommend Favorite

The importance of applying toxicogenomics to increase the efficiency of drug discovery

By Barros Scott A

Pharmacogenomics, Vol. 6, Iss. 6, 2005-09 ,pp. : 547-550

Future Medicine

Access to resources Recommend Favorite

Toxicogenomics: an opportunity to optimise drug development and safety evaluation

By Kolaja Kyle L Kramer Jeffrey A

Expert Opinion on Drug Safety, Vol. 1, Iss. 3, 2002-09 ,pp. : 275-286

Informa Healthcare

Access to resources Recommend Favorite

The future of plant drug discovery

By Littleton John

Expert Opinion on Drug Discovery, Vol. 2, Iss. 5, 2007-05 ,pp. : 673-683

Informa Healthcare

Access to resources Recommend Favorite

Open Access High Throughput Drug Discovery in the Public Domain: A Mount Everest in the Making

Current Pharmaceutical Biotechnology, Vol. 11, Iss. 7, 2010-01 ,pp. : 764-778

Bentham Science Publishers

Access to resources Recommend Favorite